SEARCH SITE
VIRGINIA LAW PORTAL
- Code of Virginia
- Virginia Administrative Code
- Constitution of Virginia
- Charters
- Authorities
- Compacts
- Uncodified Acts
- RIS Users (account required)
SEARCHABLE DATABASES
- Bills & Resolutions
session legislation - Bill Summaries
session summaries - Reports to the General Assembly
House and Senate documents - Legislative Liaisons
State agency contacts
ACROSS SESSIONS
- Subject Index: Since 1995
- Bills & Resolutions: Since 1994
- Summaries: Since 1994
Developed and maintained by the Division of Legislative Automated Systems.
2005 SESSION
055515820Be it enacted by the General Assembly of Virginia:
1. That §§ 18.2-247, 54.1-3457 and 54.1-3458 of the Code of Virginia are amended and reenacted as follows:
§ 18.2-247. Use of terms "controlled substances," "marijuana," "Schedules I, II, III, IV, V and VI," and "imitation controlled substance" in Title 18.2.
A. Wherever the terms "controlled substances" and "Schedules I, II, III, IV, V and VI" are used in Title 18.2, such terms refer to those terms as they are used or defined in the Drug Control Act (§ 54.1-3400 et seq.).
B. The term "imitation controlled substance" when
used in this article means (i) a counterfeit controlled substance or (ii) a
pill, capsule, tablet, or substance in any form whatsoever which is not a
controlled substance subject to abuse, and:
1. Which by overall dosage unit appearance, including color, shape, size, marking and packaging or by representations made, would cause the likelihood that such a pill, capsule, tablet, or substance in any other form whatsoever will be mistaken for a controlled substance unless such substance was introduced into commerce prior to the initial introduction into commerce of the controlled substance which it is alleged to imitate; or
2. Which by express or implied representations purports to act like a controlled substance as a stimulant or depressant of the central nervous system and which is not commonly used or recognized for use in that particular formulation for any purpose other than for such stimulant or depressant effect, unless marketed, promoted, or sold as permitted by the United States Food and Drug Administration.
C. In determining whether a pill, capsule, tablet, or substance in any other form whatsoever, is an "imitation controlled substance," there shall be considered, in addition to all other relevant factors, comparisons with accepted methods of marketing for legitimate nonprescription drugs for medicinal purposes rather than for drug abuse or any similar nonmedicinal use, including consideration of the packaging of the drug and its appearance in overall finished dosage form, promotional materials or representations, oral or written, concerning the drug, and the methods of distribution of the drug and where and how it is sold to the public.
D. The term "marijuana" when used in this article means any part of a plant of the genus Cannabis, whether growing or not, its seeds or resin; and every compound, manufacture, salt, derivative, mixture, or preparation of such plant, its seeds, or its resin. Marijuana shall not include any oily extract containing one or more cannabinoids unless such extract contains less than 12 percent of tetrahydrocannabinol by weight, or the mature stalks of such plant, fiber produced from such stalk, oil or cake made from the seed of such plant, unless such stalks, fiber, oil or cake is combined with other parts of plants of the genus Cannabis.
E. The term "counterfeit controlled substance"
means a controlled substance that, without authorization, bears, is packaged in
a container or wrapper that bears, or is otherwise labeled to bear, the
trademark, trade name, or other identifying mark, imprint or device or any
likeness thereof, of a drug manufacturer, processor, packer, or distributor
other than the manufacturer, processor, packer, or distributor who did in fact
so manufacture, process, pack or distribute such drug.
§ 54.1-3457. Prohibited acts.
A. For the purposes of this chapter, "counterfeit drug" means a substance which, or the container or labeling of which, without authorization, bears the trademark, trade name, or other identifying mark, imprint, number, or device, or any likeness thereof, of a manufacturer, distributor, or dispenser other than the person or persons who in fact manufactured, distributed, or dispensed such substance, and which thereby purports or is represented to be a prescription drug as defined in § 54.1-3401, or the product of, or to have been distributed by, such other manufacturer, distributor, or dispenser of such prescription drug.
B. The following acts shall be prohibited:
1. The manufacture, sale, or delivery, holding, or offering for sale of any drug, device, or cosmetic that is adulterated or misbranded.
2. The adulteration or misbranding of any drug, device, or cosmetic.
3. The receipt in commerce of any drug, device, or cosmetic that is adulterated or misbranded, and the delivery or proffered delivery thereof for pay or otherwise.
4. The sale, delivery for sale, holding for sale, or offering for sale of any article in violation of § 54.1-3421.
5. The dissemination of any false advertisement.
6. The refusal to permit entry or inspection, or to permit the taking of a sample, or to permit access to or copying of any record.
7. The giving of a false guaranty or undertaking.
8. The removal or disposal of a detained article in violation of § 54.1-3459.
9. The alteration, mutilation, destruction, obliteration, or removal of the whole or any part of the labeling of, or the doing of any other act with respect to a drug, device, or cosmetic, if such act is done while such article is held for sale and results in such article being adulterated or misbranded.
10. The forging, counterfeiting, simulating, or falsely
representing, or without proper authority using any mark, stamp, tag, label, or
other identification device authorized or required by regulations promulgated
under the provisions of this chapter or of the federal act.
1110. The using by any person to his own
advantage, or revealing, other than to the Board or its authorized
representative or to the courts when relevant in any judicial proceeding under
this chapter of any information acquired under authority of this chapter
concerning any method or process which as a trade secret is entitled to
protection.
1211. The using, on the labeling of any drug or
in any advertisement relating to such drug, of any representation or suggestion
that an application with respect to such drug is effective under § 54.1-3421,
or that such drug complies with the provisions of such section.
1312. In the case of a drug distributed or
offered for sale in this the Commonwealth, the failure of the
manufacturer, packer, or distributor thereof to maintain for transmittal, or to
transmit, to any practitioner licensed by applicable law to administer such
drug who makes written request for information as to such drug, true and
correct copies of all printed matter which is required to be included in any
package in which that drug is distributed or sold, or such other printed matter
as is approved under the federal act. This subdivision shall not be construed
to exempt any person from any labeling requirement imposed by or under other
provisions of this chapter.
1413. Placing or causing to be placed upon any
drug or device or container, with intent to defraud, the trade name or other
identifying mark, or imprint of another or any likeness of any of the
foregoing; or selling, dispensing, disposing of or causing to be sold,
dispensed or disposed of, or concealing or keeping in possession, control or
custody, with intent to sell, dispense or dispose of, any drug, device or any
container thereof, with knowledge that the trade name or other identifying mark
or imprint of another or any likeness of any of the foregoing has been placed
thereon in a manner prohibited by this section or making, selling, disposing
of, or causing to be made, sold or disposed of, or keeping in possession,
control or custody, or concealing any punch, die, plate, stone, or other thing
designed to print, imprint, or reproduce the trademark, trade name, or other
identifying mark, imprint, or device of another or any likeness of any of the
foregoing upon any drug or container or labeling thereof so as to render such
drug a counterfeit drug.
15. The doing of any act which causes a drug to be a
counterfeit drug, or the sale or dispensing, or the holding for sale or
dispensing, of a counterfeit drug.
14. Manufacturing, selling, distributing, dispensing, facilitating the distribution or dispensing, or holding for distribution or dispensing any counterfeit drug as defined in this section.
1615. Dispensing or causing to be dispensed a
different drug or brand of drug in place of the drug or brand of drug ordered
or prescribed without the permission of the person ordering or prescribing,
except as provided in § 54.1-3408.03 relating to dispensing of therapeutically
equivalent drugs.
§ 54.1-3458. Violations; increased penalty.
A. Any person who violates any of the provisions of § 54.1-3457 shall be guilty of a Class 2 misdemeanor, except that any person who knowingly and willfully violates subdivision B 13 or B 14 of § 54.1-3457 shall be guilty of a Class 5 felony.
B. No person shall be subject to the penalties of this section
for having violated subdivisions B 1 and B 3 of § 54.1-3457 if he
establishes a guaranty or undertaking signed by, and containing the name and
address of, the person residing in this the Commonwealth from
whom he received in good faith the article, to the effect that such article is
not adulterated or misbranded within the meaning of this chapter.
C. No publisher, radio-broadcast licensee, or agency or medium
for the dissemination of an advertisement, except the manufacturer, packer,
distributor, or seller of the article to which a false advertisement relates,
shall be liable under this section for the dissemination of such false
advertisement, unless he has refused, on the request of the Board, to furnish
the Board the name and post-office address of the manufacturer, packer,
distributor, seller, or advertising agency, residing in this the
Commonwealth who caused him to disseminate such advertisement.
2. That the provisions of this act may result in a net increase in periods of imprisonment or commitment. Pursuant to § 30-19.1:4, the estimated amount of the necessary appropriation cannot be determined for periods of imprisonment in state adult correctional facilities and is $0 for periods of commitment to the custody of the Department of Juvenile Justice.